熱門資訊> 正文

MoonLake免疫治疗学GAAP每股收益为-0.84美元

2026-08-10 19:12

MoonLake Immunotherapeutics press release (MLTX): Q2 GAAP EPS of -$0.84.
MoonLake ended the second quarter with $537.0 million in cash, cash equivalents and short-term marketable debt securities and expects to have a cash runway to mid-2028; additionally, up to $400 million in non-dilutive funds remain available through its debt facility with Hercules Capital

More on MoonLake Immunotherapeutics

MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion
MoonLake Immunotherapeutics: Label Upside Drives The Next Leg Higher
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow
MoonLake Immunotherapeutics prices $200M public offering of Class A shares
Stocks to watch on Monday after hours: MLTX, BBY, and DPZ

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。